The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation
- Author
- IMAI, Yasuo1 ; YOSHIMORI, Mayumi1 ; FUKUDA, Kazunori2 ; YAMAGISHI, Hidetsugu1 ; UEDA, Yoshihiko1
[1] Department of Pathology and, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Saitama 343-8555, Japan
[2] Joint Research Center, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Saitama 343-8555, Japan - Source
Oncology reports. 2012, Vol 27, Num 6, pp 1703-1709, 7 p ; ref : 33 ref
- ISSN
- 1021-335X
- Scientific domain
- Medical oncology
- Publisher
- Spandidos, Athens
- Publication country
- Greece
- Document type
- Article
- Language
- English
- Author keyword
- LY294002 PI3K/Akt breast cancer resistance protein drug resistance
- Keyword (fr)
- 1-Phosphatidylinositol 3-kinase Akt protein kinase Cancérologie Cytogénétique Inhibiteur Résistance traitement Réversibilité Translocation chromosomique Gène ABCG2 Protéine BCRP Aberration chromosomique Chromosome anormal Enzyme Transferases
- Keyword (en)
- 1-Phosphatidylinositol 3-kinase Akt protein kinase Cancerology Cytogenetics Inhibitor Treatment resistance Reversibility Chromosome translocation ABCG2 gene Breast cancer resistance protein Chromosomal aberration Abnormal chromosome Enzyme Transferases
- Keyword (es)
- 1-Phosphatidylinositol 3-kinase Akt protein kinase Cancerología Citogenética Inhibidor Resistencia tratamiento Reversibilidad Translocación cromosómica Gen ABCG2 Aberración cromosómica Cromosoma anormal Enzima Transferases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B23 Medical genetics / 002B23B Chromosome aberrations
- Discipline
- Medical genetics Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 25835691
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:107:\"The PI3K\/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation\";s:9:\"\u0000*\u0000jtitle\";s:16:\"Oncology reports\";s:9:\"\u0000*\u0000stitle\";s:10:\"Oncol. rep\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1703\";s:8:\"\u0000*\u0000epage\";s:4:\"1709\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1021-335X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"IMAI\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Yasuo\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:17:\"YOSHIMORI, Mayumi\";i:1;s:16:\"FUKUDA, Kazunori\";i:2;s:20:\"YAMAGISHI, Hidetsugu\";i:3;s:15:\"UEDA, Yoshihiko\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:107:\"The PI3K\/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation\";s:8:\"\u0000*\u0000place\";s:6:\"Athens\";s:6:\"\u0000*\u0000pub\";s:9:\"Spandidos\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:107:\"The PI3K\/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation\";s:9:\"\u0000*\u0000jtitle\";s:16:\"Oncology reports\";s:9:\"\u0000*\u0000stitle\";s:10:\"Oncol. rep\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1703\";s:8:\"\u0000*\u0000epage\";s:4:\"1709\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1021-335X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"IMAI\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Yasuo\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:17:\"YOSHIMORI, Mayumi\";i:1;s:16:\"FUKUDA, Kazunori\";i:2;s:20:\"YAMAGISHI, Hidetsugu\";i:3;s:15:\"UEDA, Yoshihiko\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:107:\"The PI3K\/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation\";s:8:\"\u0000*\u0000place\";s:6:\"Athens\";s:6:\"\u0000*\u0000pub\";s:9:\"Spandidos\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:107:\"The PI3K\/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation\";s:9:\"\u0000*\u0000jtitle\";s:16:\"Oncology reports\";s:9:\"\u0000*\u0000stitle\";s:10:\"Oncol. rep\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1703\";s:8:\"\u0000*\u0000epage\";s:4:\"1709\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1021-335X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"IMAI\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Yasuo\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:17:\"YOSHIMORI, Mayumi\";i:1;s:16:\"FUKUDA, Kazunori\";i:2;s:20:\"YAMAGISHI, Hidetsugu\";i:3;s:15:\"UEDA, Yoshihiko\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:107:\"The PI3K\/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation\";s:8:\"\u0000*\u0000place\";s:6:\"Athens\";s:6:\"\u0000*\u0000pub\";s:9:\"Spandidos\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:107:\"The PI3K\/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation\";s:9:\"\u0000*\u0000jtitle\";s:16:\"Oncology reports\";s:9:\"\u0000*\u0000stitle\";s:10:\"Oncol. rep\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1703\";s:8:\"\u0000*\u0000epage\";s:4:\"1709\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1021-335X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"IMAI\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Yasuo\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:17:\"YOSHIMORI, Mayumi\";i:1;s:16:\"FUKUDA, Kazunori\";i:2;s:20:\"YAMAGISHI, Hidetsugu\";i:3;s:15:\"UEDA, Yoshihiko\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:107:\"The PI3K\/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation\";s:8:\"\u0000*\u0000place\";s:6:\"Athens\";s:6:\"\u0000*\u0000pub\";s:9:\"Spandidos\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:107:\"The PI3K\/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation\";s:9:\"\u0000*\u0000jtitle\";s:16:\"Oncology reports\";s:9:\"\u0000*\u0000stitle\";s:10:\"Oncol. rep\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1703\";s:8:\"\u0000*\u0000epage\";s:4:\"1709\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1021-335X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"IMAI\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Yasuo\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:17:\"YOSHIMORI, Mayumi\";i:1;s:16:\"FUKUDA, Kazunori\";i:2;s:20:\"YAMAGISHI, Hidetsugu\";i:3;s:15:\"UEDA, Yoshihiko\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:107:\"The PI3K\/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation\";s:8:\"\u0000*\u0000place\";s:6:\"Athens\";s:6:\"\u0000*\u0000pub\";s:9:\"Spandidos\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
